Kerrin Rennie Award finalists nominated
Media Release
2 September 2010
Life extending and improving technology shortlisted
A temporary artificial heart, a pacemaker that can be used safely in MRI scanners, a treatment for osteoarthritic pain and a cochlear hearing system are the finalists of the 2010 Kerrin Rennie Award for Excellence in Medical Technology.
The award finalists were announced by the Medical Technology Association of Australia (MTAA) in the lead up to the conference MedTech 2010: A history of innovation – looking forward, looking back, to be held from Wednesday 15 – Thursday 16 September 2010. The winner will be announced at the conference dinner on 15 September at the Star City Hotel in Sydney.
“The shortlisted medical technologies are great examples of innovative solutions to save and improve patients’ lives,” said Anne Trimmer, MTAA CEO.
“The quality of submissions to this year’s award is a testament to the commitment of medical technology companies to medical innovation and provision of more effective treatment options for patients,” Ms Trimmer concluded.
The 2010 Kerrin Rennie Award finalists are:
Nucleus 5 System – Cochlear
The Nucleus 5 system consists of four components: Cochlear implant, sound processor, remote assistant and software. It restores hearing to individuals with severe to profound hearing loss. The Nucleus 5 includes the world’s thinnest implant and dual omni directional microphones simplifying phone use. It has increased impact, water and sweat resistance.
SureScan Pacing System – Medtronic
The SureScan Pacing system is an MRI compatible pacemaker. It is designed to overcome complications associated with MRI scans allowing previously restricted pacemaker patients to undergo less invasive and more effective diagnosis.
SynCardia – Device Technologies
SynCardia is a temporary total artificial heart enabling patients with end-stage heart disease to survive until a replacement heart becomes available. The device temporarily replaces both failing heart ventricles and heart valves. Its high volume blood flow helps patients recover to become better transplant candidates.
Synvisc One - Genzyme
Synvisc One is a gel like fluid that treats the cause of pain and decrease in join mobility associated with osteoarthritis. The gel simulates healthy synovial fluid in affected joints. Synvisc One requires fewer injections lasting up to six months.
The Kerrin Rennie Award for Excellence in Medical Technology – Improving Quality of Life recognises the innovative and extraordinary contribution of medical technology in improving health outcomes of Australian patients.
This award is endowed by the family of the late Kerrin Rennie, who was a long standing member of the Australian medical technology community. The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry.
